Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

274
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
274
Hepatic Portal System01:21

Hepatic Portal System

5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

243
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
243
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

572
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
572
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

309
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
309
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The influence of exercise modality on the inflammatory response to high-intensity interval training.

ImmunoHorizons·2026
Same author

Disease Outcomes After Segmental Resection of Colonic Crohn's Disease: A Retrospective Multicenter Study.

Inflammatory bowel diseases·2025
Same author

Relationship between changes in neuromuscular factors and disability outcomes following a resistance exercise intervention in rotator cuff tendinopathy.

Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology·2025
Same author

Females who have undergone anterior cruciate ligament reconstruction exhibit altered patellofemoral joint contact area and alignment.

Clinical biomechanics (Bristol, Avon)·2025
Same author

Use of Biologics for the Treatment of Inflammatory Conditions of the Pouch: A Systematic Review.

Journal of clinical gastroenterology·2023
Same author

Advances in Imaging of Inflammation, Fibrosis, and Cancer in the Gastrointestinal Tract.

International journal of molecular sciences·2022
Same journal

How important is fiber in the Crohn's disease story?

Gastroenterology·2026
Same journal

Reply to "Critical Appraisal of the Integrin αV-YAP-CTGF Axis in Congestive Hepatopathy".

Gastroenterology·2026
Same journal

Critical Appraisal of the Integrin αV-YAP-CTGF Axis in Congestive Hepatopathy.

Gastroenterology·2026
Same journal

A High-Risk Impaction: To Scope or to Stent First?

Gastroenterology·2026
Same journal

Epithelial FOXP3 orchestrates O-glycosylated IL-6 secretion to drive pancreatic fibrocarcinogenesis.

Gastroenterology·2026
Same journal

Reply to "Methodological Considerations on Neonatal Metabolomics and Future Inflammatory Bowel Disease".

Gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Jan 31, 2026

Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K

Hepatitis C, and Cannot See!

George Salem1, Laura J Adhikari2

  • 1Section of Digestive Diseases & Nutrition, Department of Internal Medicine, Oklahoma City, Oklahoma.

Gastroenterology
|January 6, 2019
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Related Experiment Videos

Last Updated: Jan 31, 2026

Murine Bioluminescent Hepatic Tumour Model
05:23

Murine Bioluminescent Hepatic Tumour Model

Published on: July 17, 2010

17.8K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.8K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K